783 / 1631
JULIET: Study design (Novartis)
A longer than expected period between enrolment and infusion occurred due to manufacturing delays
a
To be completed 2 to 14 days prior to tisagenlecleucel infusion
b
Infusion conducted on an in- or outpatient basis at investigator discretion
Pts eligible after ≥2
lines chemotherapy,
ineligible for or failed
auto-SCT
CD19 4-1BB, first approved CAR-T (child +TYA) B-ALL